ASTRAZEN - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 3.0
✅ Positive
The stock demonstrates a positive trend with increasing volume, suggesting momentum. Furthermore, the recent news regarding SEBI-compliant dematerialization and CDSCO approval for a new breast cancer treatment drug is favorable.
⚠️ Limitation
Despite the upward price movement and encouraging financials like strong ROCE and ROE, the high P/E ratio of 108 indicates potential overvaluation. The negative Qtr Profit Variance (-26.6%) also raises concerns regarding future growth prospects.
📉 Company Negative News
AstraZeneca Pharma India’s news highlights a -26.6% quarter-on-quarter profit variance, indicating recent underperformance. Additionally, the SEBI-compliant dematerialization is related to a specific product launch and doesn't necessarily translate into broader revenue growth.
📈 Company Positive News
AstraZeneca Pharma India confirms SEBI-compliant dematerialization for Q1 FY27, streamlining processes for distribution. The CDSCO nod allows for importing and distributing a breast cancer treatment drug, potentially expanding the company’s portfolio.
🏭 Industry
The pharmaceutical industry is generally considered stable but subject to regulatory changes and patent expirations. Pharma companies often show strong growth potential driven by innovation and increasing healthcare demand within India.
🧾 Conclusion
A buy price of 8,270 ₹ would be suitable considering the current momentum and DMA support at 8,255 ₹. An initial exit level at 8,600 ₹ could target a profit of approximately 3.9%. Alternatively, implement a stop-loss order at 8,150 ₹ to limit potential losses if the upward momentum falters. Overall, while promising, careful monitoring is advised due to the high P/E ratio.